Key Takeaways
-
Start BPO planning early and strategically: BPO pharma conversations should begin 18–24 months before launch, guided by channel strategy. A cross-functional oversight group — even a small one — ensures accountability across operations, finance, and market access when lean teams blur role boundaries.
-
Retain control of data and judgment: In BPO pharma arrangements, companies should keep raw data access, business rules, Gross-to-Net strategy, government pricing policy, and governance in-house. Outsource repeatable mechanics like data aggregation, chargeback processing, and operational reporting to your BPO partner.
-
Reassess and adapt as you grow: BPO pharma relationships should evolve post-launch. Revisit your partnership one to two years after launch, watch for red flags like poor communication and missed deadlines, and rebalance insource versus outsource decisions as your portfolio, channel strategy, and organizational needs change.
For emerging pharmaceutical companies, the journey from pre-commercial to post-launch is filled with high-stakes operational choices. One of the most consequential is whether and how to outsource essential business processes. The right BPO (Business Process Outsourcing) partner(s) can reduce operational strain, accelerate timelines, and help ensure compliance in a demanding regulatory landscape.
When considering and evaluating a BPO, there are some key questions that should guide your thinking:
- What business functions are needed to support my near-term and longer-term product(s), and which are likely to be the most complicated or critical to success?
- Which BPO vendor(s) has/have strength in the specific areas that best suit our company and product profile?
- What functions and data should remain in-house?
- Should we identify a single BPO vendor, or do the specific needs of my product warrant consideration of a best-of-breed approach by operational area?
The pre-commercial BPO relationship
The earliest conversations about outsourcing should happen 18–24 months before a potential launch. At this stage, determining what to retain in-house and what to delegate is especially pivotal.
Emerging pharmaceutical companies often operate with lean teams, meaning BPO oversight can land across multiple functions — operations, finance, and market access — with frequent role overlap. In some cases, no single owner is accountable for certain business functions, so alignment of a BPO relationship owner can be challenging. Sometimes the finance lead is doubling as the contracts manager, so accountability often falls wherever someone has the bandwidth and not necessarily the expertise.
The solution? A proactive cross-functional oversight group, even a small one, to monitor service delivery, compliance, and performance.
Why BPO strategy matters for operational success
BPO planning should always start with the brand’s channel strategy, as channel strategy and operational design are tightly linked. Whether distributing through retail, specialty pharmacy, direct-to-consumer, or a hybrid model, each path requires distinct contracting strategies, rebate structures, and regulatory submissions.
Once your channel strategy is locked, it drives a whole cascade of decisions about processes and systems. Outsourcing some of that is smart but only if you know what to hold onto. Most importantly, when choosing a BPO, ensure their standard processes don’t limit your own policies. Don’t accept a cookie-cutter workflow if your strategy demands customization.
What to keep in-house vs. outsource
Even with extensive outsourcing, pharma companies must retain control of their data. Outsourcers are stewards of your data, not owners of it.
Keep in-house:
- Raw data access (chargebacks, claims, sales feeds)
- Business rules and policy definitions
- Gross-to-Net strategy and validation
- Government Pricing policy and oversight
- Governance and approvals
Outsource:
- Data aggregation
- Government pricing calculations
- Chargeback and rebate processing
- Operational report generation
You can’t manage what you can’t see. Retain the pieces where judgment and speed matter most. Let your BPO handle the repeatable mechanics. While this might sound sensible, engaging with an objective trusted advisor can also be important to ensure setup of the BPO arrangement formally defines services, roles, and responsibilities in a way that meets the needs of your company.
Post-launch considerations for your current BPO relationship
Pharmaceutical manufacturers, especially emerging pharma companies, should always reevaluate operational decisions including their BPO partner post launch. You should revisit your partnership and insource/outsource decision one to two years after launch. First, you should evaluate your partner’s performance to ensure they are consistently meeting your agreed-upon expectations for delivery and service. Additionally, company growth and sustained success after launch are great times to reconsider prior outsourcing decisions and ensure they meet your current needs.
You should be asking yourself these questions about your BPO relationship:
- Is my BPO vendor fulfilling the services they’ve been hired to perform?
- Does my organization have the right level of visibility into process inputs, outputs, and results to: a.) properly assess BPO performance? b.) readily answer business questions using the data from BPO processing?
- Based on the answers to items 1–2, does our contract and/or statement of work with the BPO require updating?
- Did or will our channel strategy change for our current product?
- Are we adding products to our portfolio that will cause us to reconsider our current approach or financial commitment?
Current BPO performance: Signs it’s time to reassess
A BPO relationship can unravel slowly or all at once. Here are the most common red flags:
- Poor Communication: Delays in responses, unclear answers, or broken feedback loops.
- Missed Deadlines: Late government filings or payment processing can trigger penalties or fines.
- Inaccurate Reporting: Misaligned data or reports that don’t reflect actual performance.
- Lack of Visibility: You don’t know what’s happening behind the scenes or can’t access raw data.
- Reactive Service: They “do what’s asked” but offer no proactive insights or improvements.
Sometimes the relationship just needs a process reengineering — better approvals, more transparency, more ownership.
How to evaluate (and fix) a BPO relationship
Instead of immediately replacing an underperforming partner, consider conducting a structured operational assessment. Start by asking:
- What data am I receiving? Can I trace it back to the source?
- Are reports timely, complete, and aligned to the questions I need answered?
- Are rebate payments accurate and properly validated?
- Are government submissions on time and compliant?
If the answer to any of these or similar questions is “no,” the issue may be fixable — with support. An independent third party can help redefine approval workflows, revalidate processes, and reestablish expectations.
Organizational change
Whether your launch didn’t unfold as expected, your strategy has shifted, or your organization is growing with an expanding portfolio, these are all valid reasons to reassess your current BPO partnership.
When launch performance, positive or negative, doesn’t align with expectations, it often prompts a reevaluation of patient access strategies. Changes to distribution, channel mix, or payer approach can quickly create misalignment with your existing BPO agreement or your BPO vendor’s capabilities.
Examples of strategy-driven changes that may necessitate reshaping your BPO model include:
- Expanding contract strategies to new customers or channels
- Adding distribution partners or alternative delivery models
Each new customer contract increases payment, invoicing, and data complexity, while also impacting government pricing. The question is: can your current BPO partner manage these changes effectively both operationally and financially? Every company’s assumptions at launch are wrong to some degree. The key is knowing when and how to adapt.
Portfolio growth
As emerging pharmaceutical companies expand their pipelines and prepare to commercialize additional assets, it often becomes necessary to reassess the current BPO relationship. Increased scale and complexity may stretch whether your existing arrangement can fully support the demands of a broader portfolio.
While your current BPO arrangement might have worked for a single product, it may not scale across multiple assets. With each new product comes added demands in contracting, distribution, data management, and compliance. This raises the question of which functions should remain in-house and which should be outsourced.
Examples of portfolio-driven changes that may require rethinking your BPO model include:
- Expanding patient services across therapeutic areas
- Increased complexity in contracting and government pricing
- Additional distribution partners and data integration needs
Balancing internal capabilities with outsourced support is key to ensuring scalability, while maintaining quality, compliance, and cost efficiency. As companies grow their portfolios, the same playbook rarely applies. The challenge is building a model that adapts without breaking.
Don’t Fear Change — Plan for It
BPO relationships should evolve. As your product matures, new indications launch, or patient access channels shift, so must your operational model. If something doesn’t feel right, don’t let the fear of change hold you back. You don’t always have to break up — sometimes you just need help fixing it.
Contact usFAQs on business process outsourcing (BPO)in pharma
What is BPO in pharma and why is it important?
BPO in pharma is the outsourcing of essential business processes like data aggregation, government pricing calculations, and chargeback processing to specialized partners. It helps emerging manufacturers reduce operational strain, accelerate timelines, and ensure regulatory compliance during and after launch.
When should BPO pharma planning begin?
BPO pharma conversations should start 18–24 months before a potential launch. Early planning allows companies to determine what to retain in-house, what to delegate, and how to structure cross-functional oversight before operational demands intensify.
What functions should pharma companies keep in-house vs. outsource?
Keep raw data access, business rules, Gross-to-Net strategy, government pricing policy, and governance in-house. Outsource repeatable mechanics like data aggregation, chargeback and rebate processing, government pricing calculations, and operational report generation to your BPO partner.
What are the red flags that a BPO pharma relationship needs reassessment?
Common red flags include poor communication, missed deadlines, inaccurate reporting, lack of visibility into processes, and reactive service. If these appear, conduct a structured operational assessment before deciding whether to fix or replace the partnership.
How often should you reassess your BPO pharma partnership?
Revisit your BPO pharma partnership one to two years after launch, and whenever your channel strategy shifts, your portfolio expands, or your launch results diverge from expectations. Regular reassessment ensures your outsourcing model keeps pace with your evolving business needs.